SSY GROUP (02005): Ziprasidone Mesylate Approved as API for Use in Marketed Formulations

SSY GROUP (02005) announced that the Group's Ziprasidone Mesylate has been approved by China's National Medical Products Administration for registration as an API for use in marketed formulations. Ziprasidone Mesylate is primarily used for the treatment of acute agitation in patients with schizophrenia. This approval further enhances the Group's second-generation antipsychotic high-potency API (HPAPI) product matrix. Currently, the Group has established a leading domestic second-generation antipsychotic HPAPI platform, covering Blonanserin, Lurasidone, Ziprasidone Hydrochloride, and the newly approved Ziprasidone Mesylate, continuously providing high-quality API supply chain support for domestic formulation companies.